JP2010540649A - ｃ−ＭＥＴタンパク質の阻害剤 - Google Patents

ｃ−ＭＥＴタンパク質の阻害剤 Download PDF

Info

Publication number
JP2010540649A
JP2010540649A JP2010528066A JP2010528066A JP2010540649A JP 2010540649 A JP2010540649 A JP 2010540649A JP 2010528066 A JP2010528066 A JP 2010528066A JP 2010528066 A JP2010528066 A JP 2010528066A JP 2010540649 A JP2010540649 A JP 2010540649A
Authority
JP
Japan
Prior art keywords
compound
mmol
aliphatic
pharmaceutically acceptable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010528066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540649A5 (Direct
Inventor
デイビッド ローファー，
パン リー，
ナザン ワール，
キラ マクギンティー，
チン タン，
スティーブン ロンキン，
リュック ファーマー，
ディーン シャノン，
ディラン ジェイコブ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2010540649A publication Critical patent/JP2010540649A/ja
Publication of JP2010540649A5 publication Critical patent/JP2010540649A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2010528066A 2007-10-03 2008-09-30 ｃ−ＭＥＴタンパク質の阻害剤 Pending JP2010540649A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97730507P 2007-10-03 2007-10-03
PCT/US2008/078239 WO2009045992A2 (en) 2007-10-03 2008-09-30 C-met protein kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2010540649A true JP2010540649A (ja) 2010-12-24
JP2010540649A5 JP2010540649A5 (Direct) 2012-10-18

Family

ID=40512401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528066A Pending JP2010540649A (ja) 2007-10-03 2008-09-30 ｃ−ＭＥＴタンパク質の阻害剤

Country Status (12)

Country Link
US (1) US8481524B2 (Direct)
EP (1) EP2205589B1 (Direct)
JP (1) JP2010540649A (Direct)
CN (1) CN101990538A (Direct)
AT (1) ATE502935T1 (Direct)
AU (1) AU2008308900A1 (Direct)
CA (1) CA2701124A1 (Direct)
DE (1) DE602008005786D1 (Direct)
ES (1) ES2361650T3 (Direct)
MX (1) MX2010003563A (Direct)
NZ (1) NZ584311A (Direct)
WO (1) WO2009045992A2 (Direct)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506381A (ja) * 2008-10-21 2012-03-15 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−ＭＥＴタンパク質キナーゼ阻害剤

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534516T3 (es) 2010-01-07 2015-04-23 E.I. Du Pont De Nemours And Company Compuestos heterocíclicos fungicidas
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
JP5965499B2 (ja) 2012-12-25 2016-08-03 日本曹達株式会社 ハロゲン化アニリンおよびその製造方法
CN103242216A (zh) * 2013-05-07 2013-08-14 兰州梦唐精细化工有限公司 N- Boc -六氢-5-氧代环戊[C]并吡咯的合成方法
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
JP6660060B2 (ja) 2014-09-16 2020-03-04 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506763A (ja) * 2003-09-24 2007-03-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なイミダゾール組成物
JP2007508344A (ja) * 2003-10-17 2007-04-05 エフ．ホフマン−ラ　ロシュ　アーゲー 新規イミダゾール誘導体及び医薬品としてのそれらの使用
WO2007111904A2 (en) * 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007506763A (ja) * 2003-09-24 2007-03-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なイミダゾール組成物
JP2007508344A (ja) * 2003-10-17 2007-04-05 エフ．ホフマン−ラ　ロシュ　アーゲー 新規イミダゾール誘導体及び医薬品としてのそれらの使用
WO2007111904A2 (en) * 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506381A (ja) * 2008-10-21 2012-03-15 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−ＭＥＴタンパク質キナーゼ阻害剤

Also Published As

Publication number Publication date
US8481524B2 (en) 2013-07-09
DE602008005786D1 (de) 2011-05-05
AU2008308900A1 (en) 2009-04-09
CA2701124A1 (en) 2009-04-09
EP2205589B1 (en) 2011-03-23
US20110136789A1 (en) 2011-06-09
ATE502935T1 (de) 2011-04-15
WO2009045992A2 (en) 2009-04-09
CN101990538A (zh) 2011-03-23
MX2010003563A (es) 2010-06-02
WO2009045992A3 (en) 2009-06-04
ES2361650T3 (es) 2011-06-21
NZ584311A (en) 2012-03-30
EP2205589A2 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
US8232406B2 (en) c-MET protein kinase inhibitors
US8518938B2 (en) c-MET protein kinase inhibitors
US8481524B2 (en) c-MET protein kinase inhibitors
US20210015792A1 (en) OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL
US8263777B2 (en) Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase
CN102448968A (zh) C-met蛋白激酶的取代的吡唑抑制剂
RS53011B (sr) Aminopirazol triazolotiadiazol inhibitori c-met protein kinaze
HK1151519A (en) C-met protein kinase inhibitors
HK1129890B (en) C-met protein kinase inhibitors for the treatment of proliferative disorders
HK1161257A (en) C-met protein kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131029